II-VI, Inc. (IIVI) PT Raised to $45 at Needham & Company Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
II-VI (IIVI) 3D Sensing Comments a Near-Term Positive for Lumentum (LITE) - Stifel
August 7, 2017 1:23 PM EDTStifel analyst Patrick Newton views II-VI's (NASDAQ: IIVI) results as incrementally positive for Lumentum Holdings (NASDAQ: LITE), and to a lesser extent Finisar (NASDAQ: FNSR), in the near-term given constructive commentary on the 3D sensing market opportunity, datacom strength,... More
Pre-Open Movers 08/07: (MYOK) (NXTM) (COL) Higher; (ZYNE) (GEMP) (IPI) Lower (more...)
August 7, 2017 9:33 AM EDTToday's Pre-Open Stock Movers
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) 55.9% LOWER; announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures. ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo.
Gemphire Therapeutics Inc. (NASDAQ: GEMP) 38.1% LOWER;... More
II-VI, Inc. (IIVI) Tops Q4 EPS by 15c
August 7, 2017 6:56 AM EDTII-VI, Inc. (NASDAQ: IIVI) reported Q4 EPS of $0.50, $0.15 better than the analyst estimate of $0.35. Revenue for the quarter came in at $273.7 million versus the consensus estimate of $249.9 million.
GUIDANCE:
II-VI, Inc. sees Q1 2018 EPS of $0.30-$0.34, versus the consensus of... More
II-VI, Inc. (IIVI) Buys Kaiam's 6-inch Wafer Fabrication Facility in the U.K.
August 7, 2017 6:51 AM EDTIIVI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components, today announced its acquisition of Kaiam Laser Limited, a 6-inch wafer fabrication facility in Newton Aycliffe in the United Kingdom. The purchase price of the transaction was $80.0 million, and paid for from the Companys cash reserves. The acquisition is expected to be breakeven at the EBITDA level within 12 months.
The 300,000 square foot facility hosts a state of the art 100,000 square foot clean room designed for high volume... More
